Progress and Challenges in RSV Prophylaxis and Vaccine Development

Journal of Infectious Diseases

Volumn 208, Issue SUPPL. 3, 2013, Pages

  Haynes, Lia M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; LIVE VACCINE; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VECTOR;

ANTIBODY RESPONSE; ARTICLE; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINE PRODUCTION; VIRUS RECOMBINANT; VIRUS STRAIN; ADOLESCENT; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; MOUSE; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; YOUNG ADULT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INFANT; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; YOUNG ADULT;

EID: 84893499613     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit512     Document Type: Article

References (55)

1. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bron- chiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001; 183:16-22.
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360: 588-98.
3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-55.
4. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012; 31:5-9.
5. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22:275-84.
6. Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 2007; 39: 225-39.
7. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-59.
8. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD 14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
9. Magro M, Mas V, Vazquez M, Cano O, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci USA 2012; 109:3089-94.
10. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001; 2:732-8.
11. Behera AK, Matsuse H, Kumar M, Kong X, Lockey RF, Mohapatra SS. Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys Res Commun 2001; 280:188-95.
12. Malhotra R, Ward M, Bright H, et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect 2003; 5:123-33.
13. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. Identification of nucleolin as a cellular receptor for human respiratory syncytial vims. Nat Med 2011; 17:1132-5.
14. The Impact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7.
15. Carbonell-Estrany X, Simoes EA, Dagan R, et al.; Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125:35-51.
16. Roymans D, Koul A. Treatment of Respiratory Syncytial Virus Infection: Past, Present and Future. In: Resch B, ed. Human Respiratory Syncytial Virus Infection, Rijeka, Croatia. In Tech 2011; 197-215.
17. Patel H, Piatt R, Lozano JM, Wang EE. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004; (3):CD004878. Review. Update in: Cochrane Database Syst Rev 2008; (1):CD004878. PubMed PMID: 15266547.
18. Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2000; (2):CD001266. Review. Update in: Cochrane Database Syst Rev 2006; (3):CD001266.
19. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2004; (4):CD000181. Review. Update in: Cochrane Database Syst Rev 2007; (1):CD000181.
20. Schepens B, Ibanez LI, De Baets S, et al. Nanobodies specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis 2011; 204:1692-701.
21. Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus(RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009; 200:439-47.
22. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2010; 2:655-61.
23. Caidi H, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM. The effects of combination therapy using monoclonal antibodies against RSV G glycoprotein in BALB/c mice. PLoS One 2012; 7:e51485.
24. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
25. Delgado MF, Coviello S, Monsalve AC, et al. Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34-41.
26. Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988; 26:1595-7.
27. Neilson KA, Yunis EJ. Demonstration of respiratory syncytial virus in an autopsy series. Pediatr Pathol 1990; 10:491-502.
28. Stanberry LR, Simon JK, Johnson C, et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 2012; 30:307-16.
29. Makidon PE, Knowlton J, Groom JV 2nd, et al. Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med Microbiol Immunol 2010; 199:81-92.
30. Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine 2010; 28: 5543-50.
31. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011; 239:178-96.
32. Jones BG, Sealy RE, Rudraraju R, et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 2012; 30:959-68.
33. Luongo C, Winter CC, Collins PL, Buchholz UJ. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 2012; 86:10792-804.
34. Luongo C, Winter CC, Collins PL, Buchholz UJ. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature sensitive live-attenuated vaccine candidate that is phenotypically stable at physiological temper-ature. J Virol 2013; 87:1985-96.
35. Lindell DM, Morris SB, White MP, et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One 2011; 6:e21823.
36. Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One 2012; 7:e36812.
37. Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines 2011; 10:1415-33.
38. Garlapati S, Garg R, Brownlie R, et al. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynudeotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 2012; 30:5206-14.
39. Jorquera PA, Choi Y, Powell TJ, Haynes LM, Anderson LJ, Tripp RA. A nanoparticle vaccine encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induces robust immunity protecting from challenge and disease. PLoS One 2013; 8:e74905.
40. de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. Vaccine 2012; 30: 4884-91.
41. Mok H, Cheng X, Xu Q, et al. Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein- Barr virus glycoprotein gp350. Open Virol J 2012; 6:12-22.
42. Kohlmann R, Schwannecke S, Tippler B, et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon- optimized F protein of respiratory syncytial virus. J Virol 2009; 83: 12601-10.
43. Mok H, Lee S, Utley TJ, et al. Venezuelan equine encephalitis virus rep- licon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 2007; 81:13710-22.
44. Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000; 18:1763-72.
45. Schickli JH, Kaur J, Tang RS. Nonclinical phenotypic and genotypic analyses of a phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030ASH) at permissive and non-per- missive temperatures. Virus Res 2012; 169:38-47.
46. Karron RA, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-1104.
47. Teng MN, Whitehead SS, Bermingham A, et al. Recombinant respiratory syncytial virus that does not express the NSlor M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 2000; 74:9317-21.
48. Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012; 7: e50852.
49. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013:31:524-32.
50. Novavax Phase I RSV Vaccine Data Publish. GlobeNewsWire. Press release. Dec. 6, 2012.
51. Makidon PE, Bielinska AU, Nigavekar SS, et al. Pre-dinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:e2954.
52. Zhang W, Choi Y, Haynes LM, et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 2010; 84:1148-57.
53. Remot A, Roux X, Dubuquoy C, et al. Nudeoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine. PLoS One 2012; 7:e37722.
54. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 2011; 30:510-7.
55. Ely KH, Roberts AD, Kohlmeier JE, Blackman MA, Woodland DL. Aging and CD8+ T cell immunity to respiratory virus infections. Exp Gerontol 2007; 42:427-31.